877861-67-1

Upstream product

• 111-29-5 1 ,5-pentanediol 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 34626-51-2 5-bromopentan-1-ol 
• 1972-28-7 diethylazodicarboxylate 

Downstream Products

• 877861-68-2 methyl 4-({5-[(methylsulfonyl)oxy]pentyl}oxy)benzoate 
• 877861-72-8 methyl 4-{6-[(methylsulfonyl)oxy]hexyl}benzoate 
• 1033761-65-7 methyl 4-[(5-oxopentyl)oxy]benzoate 
• 1033761-66-8 C₁₇H₂₀O₅ 
• 1033761-77-1 C₁₆H₁₈O₅ 
• 1221398-31-7 C₃₁H₃₆O₈ 
• 98092-80-9 4-(5-hydroxypentyloxy)benzoic acid 

Relevant academic research and scientific papers

Based on isoxazole substitution of benzamide derivatives and anti-prostate cancer drug applications

The present invention discloses a class (I), formula (II) structure based on isoxazole substituted benzamide derivatives and antiprostate cancer drug applications, such isoxazole substituted benzamide derivatives, can effectively inhibit the activity of a

CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME

The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE

This invention provides substituted pyrimidine compounds that are useful in treating a patient having a disease or cancer. The compounds of this invention are useful as multi-enzyme antifolates selectively targeting the folate receptor (FR). Further, a me

POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND ORIENTED FILM

Polymerizable liquid crystal compounds represented by formula (i) and polymerizable liquid crystal compositions that contain the polymerizable compounds can provide optically anisotropic films that have excellent optical anisotropy, that stably maintain r

POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND ALIGNMENT FILM

Disclosed is a polymerizable liquid crystal compound represented by the formula [1] below, which enables to obtain a polymer having excellent optical anisotropy, excellent chemical resistance and excellent heat resistance, wherein retardation value and transparency are stably maintained even at high temperatures. (In the formula, R represents an organic group represented by the formula [A-1], [B-1], [B-2] or [C-1] below; and n represents an integer of 2 to 9.) (In the formula, X represents a hydrogen atom, a halogen atom, a cyano group or an alkoxy group; m represents an integer of 2 to 10; and p represents an integer of 0 to 6.)

COMPOUND CONTAINING BASIC GROUP AND USE THEREOF

The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

COMPOUND CONTAINING BASIC GROUP AND USE THEREOF

A compound represented by the general formula (I-0): (I-0) (wherein the symbols are as defined in the description), a salt thereof, N-oxide form thereof, or solvate thereof, or a prodrug of any of these; and a medicinal use of these. The compound has CXCR4 antagonistic activity and is hence useful, e.g., as a preventive and/or therapeutic agent for CXCR4-mediated diseases, e.g., inflammatory/immunologic diseases (e.g., articular rheumatism, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions against transplanted organs), allergic diseases, infectious diseases (e.g., human immunodeficiency virus infection and acquired immunological deficiency syndrome), mental/nervous diseases, brain diseases, cardiac/vascular diseases, metabolic diseases, and carcinomatous diseases (e.g., cancers and cancer metastasis), or as an agent for regenerative medicine.